Mounjaro 5mg: what the evidence says about this dose

What SURMOUNT-1 tells us about lower therapeutic doses of tirzepatide

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three active dose arms (5mg, 10mg and 15mg) alongside a placebo group over 72 weeks. The 5mg arm is the most instructive for anyone currently at or approaching this dose: participants on tirzepatide 5mg achieved an average body-weight reduction of around 15% by the end of the trial. That is a substantial result for what is the lowest ongoing therapeutic dose in the range.

The trial design matters here. Participants spent the first 20 weeks reaching their assigned maintenance dose, starting at 2.5mg and stepping up every four weeks. So the 5mg arm participants were, in effect, living at this dose for a meaningful stretch before the data was collected. If you are currently on Mounjaro 5mg and wondering whether results are on track, the trial data offers a genuine reference point.

NICE cited this evidence in its technology appraisal TA1026 when recommending tirzepatide for weight management in the UK. The mechanism driving those results (dual activation of the GIP and GLP-1 receptors) is fully active at 5mg, not just at the higher doses.

What actually changes when you step up from 2.5mg to 5mg

The 2.5mg pen's primary job is tolerability. It gets your body used to tirzepatide's effects on gastric emptying and appetite signalling before the dose climbs. At 5mg, the appetite-suppressing effect becomes noticeably stronger for most people. Meal portions feel smaller. The urge to snack between meals often drops. Some people describe a shift in their relationship with food that feels qualitatively different from anything willpower alone achieved.

That shift also brings a higher chance of gastrointestinal symptoms, nausea, loose stools, or a feeling of fullness that borders on uncomfortable. The NHS tirzepatide patient page notes that these effects are most common at the start of treatment or after a dose increase, and typically settle within days to a couple of weeks. Eating smaller meals, staying well hydrated and avoiding very fatty foods all help. Your prescriber or Patient Information Leaflet is the right place to look for personalised guidance.

One practical note: the KwikPen that arrives for your 5mg step-up looks almost identical to the 2.5mg one. Each pen contains four weekly doses. Delivery comes tracked via DPD the next working day, in plain, unbranded packaging, nothing on the outside signals what's inside. Worth knowing if discretion matters to you.

For context on what the 5mg pen contains in terms of volume, our page on Mounjaro volume and the KwikPen covers that in detail.

Eligibility for Mounjaro 5mg: who reaches this dose and when

Reaching the 5mg dose requires having already been assessed as suitable for tirzepatide in the first place. The licensed criteria for private prescription are broadly: adults with a BMI of 30 or above, or 27 and above with at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

After that initial assessment, the step from 2.5mg to 5mg is a clinical decision based on how the starter dose was tolerated. A prescriber who has reviewed your progress confirms the increase is appropriate. At nume, every repeat order (including a dose step) is reviewed by a GPhC-registered Independent Prescriber before anything is dispensed. A real clinician reads your update the same day; the decision is never automated.

If you are exploring whether tirzepatide is right for you at any dose, the treatment options page sets out the full picture. For those curious about what happens after 5mg, the next step up is Mounjaro 7.5mg, again subject to clinical assessment. And if you are wondering about the cost of treatment across doses, our Mounjaro access page explains how private prescription pricing works in the UK.

People also ask what happens specifically around week five of Mounjaro treatment, which often coincides with or immediately follows the move to 5mg. That timing can feel significant, and there is specific information available about what that phase typically looks like.

A note on what 5mg is not

Mounjaro 5mg is not the maintenance dose for most people. The licensed dose range runs up to 15mg, and the clinical trials found that higher doses produced greater average weight loss. That does not mean 5mg is inadequate, some people tolerate and respond well at this level and stay here longer, or permanently, on clinical advice. It means that 5mg is best understood as part of a titration journey rather than an endpoint.

Similarly, if you are only a few weeks into 5mg, it is too early to judge results. The SURMOUNT-1 data reflects outcomes over 72 weeks, not a few injection cycles. What you are likely to notice first is appetite change and some GI adjustment; weight change follows at its own pace. If you have specific questions about interactions (for example, how Mounjaro interacts with warfarin) those deserve prescriber attention rather than general reassurance.

The tirzepatide overview gives a broader look at the mechanism and the full evidence base if you want to read further. And our clinical team is available seven days a week for aftercare questions once you are in treatment.